VENCLEXTA (venetoclax tablets) for oral use or after ...

1 HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA . VENCLEXTA (venetoclax tablets), for oral use Initial Approval: 2016 RECENT MAJOR CHANGESI ndications and Usage, AML ( )Dosage and Administration ( , , , , ) 10/202011/2020 Warnings and Precautions, Tumor Lysis Syndrome ( )11/2020 Warnings and Precautions, Neutropenia ( ) 10/2020 INDICATIONS AND USAGEVENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

2 ( ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( )DOSAGE AND ADMINISTRATION See Full Prescribing Information for recommended VENCLEXTA dosages. ( , ) Take VENCLEXTA tablets orally once daily with a meal and water. Do not chew, crush, or break tablets. ( ) Provide prophylaxis for tumor lysis syndrome. ( , ) DOSAGE FORMS AND STRENGTHST ablets: 10 mg, 50 mg, 100 mg (3) CONTRAINDICATIONSC oncomitant use with strong CYP3A inhibitors at initiation and during ramp-up phase in patients with CLL/SLL is contraindicated.

3 ( , 4, ) WARNINGS AND PRECAUTIONS Tumor Lysis Syndrome (TLS): Anticipate TLS; assess risk in all patients. Premedicate with anti-hyperuricemics and ensure adequate hydration. Employ more intensive measures (intravenous hydration, frequent monitoring, hospitalization) as overall risk increases. ( , ) Neutropenia: Monitor blood counts. Interrupt dosing and resume at same or reduced dose. Consider supportive care measures. ( , ) Infections: Monitor for signs and symptoms of infection and treat promptly. Withhold for Grade 3 and 4 infection until resolution and resume at same or reduced dose.

4 ( , ) Immunization: Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery. ( ) Embryo-Fetal Toxicity: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( ) Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials. ( ) ADVERSE REACTIONSIn CLL/SLL, the most common adverse reactions ( 20%) for VENCLEXTA when given in combination with obinutuzumab or rituximab or as monotherapy were neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema.

5 ( )In AML, the most common adverse reactions ( 30%) in combination with azacitidine or decitabine or low-dose cytarabine were nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, hemorrhage, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, and hypotension. ( )To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or DRUG INTERACTIONS Strong or moderate CYP3A inhibitors or P-gp inhibitors: Adjust dosage of VENCLEXTA .

6 ( , ) Strong or moderate CYP3A inducers: Avoid co-administration. ( ) P-gp substrates: Take at least 6 hours before VENCLEXTA . ( ) USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed. ( ) Hepatic Impairment: Reduce the VENCLEXTA dose by 50% in patients with severe hepatic impairment. ( , ) See 17 for PATIENT COUNSELING INFORMATION and Medication : 11/2020 FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND Chronic Lymphocytic Leukemia/Small Lymphocytic Acute Myeloid Leukemia2 DOSAGE AND Important Safety Recommended Dosage for Chronic Lymphocytic Leukemia/Small Lymphocytic Recommended Dosage for Acute Myeloid Risk Assessment and Prophylaxis for Tumor Lysis Dosage Modifications for Adverse Dosage Modifications for Drug Dosage Modifications for Patients with Severe Hepatic Administration3 DOSAGE FORMS AND STRENGTHS4 CONTRAINDICATIONS5 WARNINGS AND Tumor Lysis Embryo-Fetal Increased Mortality in Patients with Multiple Myeloma when

7 VENCLEXTA is Added to Bortezomib and Dexamethasone6 ADVERSE Clinical Trials Experience 7 DRUG Effects of Other Drugs on Effect of VENCLEXTAon Other Drugs8 USE IN SPECIFIC Females and Males of Reproductive Pediatric Geriatric Renal Hepatic Impairment10 OVERDOSAGE11 DESCRIPTION12 CLINICAL Mechanism of Pharmacokinetics13 NONCLINICAL Carcinogenesis, Mutagenesis, Impairment of Animal Toxicology and/or Pharmacology14 CLINICAL Chronic Lymphocytic Leukemia/Small Lymphocytic Acute Myeloid Leukemia16 HOW SUPPLIED/STORAGE AND HANDLING17 PATIENT COUNSELING INFORMATION*Sections or subsections omitted from the full prescribing information are not listed.

8 FULL PRESCRIBING INFORMATION1 INDICATIONS AND Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaVENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia(CLL) or small lymphocytic lymphoma (SLL). Acute Myeloid LeukemiaVENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction DOSAGE AND Important Safety InformationAssess patient-specific factors for level of risk of tumor lysis syndrome (TLS) and provide prophylactic hydration and anti-hyperuricemics to patients prior to first dose of VENCLEXTA to reduce risk of TLS [see Dosage and Administration ( )]

9 And Warnings and Precautions ( )]. Recommended Dosage for Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaVENCLEXTA dosing begins with a 5-week ramp-up. The 5-week ramp-up dosing schedule is designed to gradually reduce tumor burden (debulk) and decrease the risk of 5-week Dose Ramp-Up ScheduleAdminister VENCLEXTA according to the 5-week ramp-up dosing schedule to the recommended dosage of 400 mg orally once daily as shown in Table 1. Table 1. Dosing Schedule for 5-Week Ramp-up Phase for Patients withCLL/SLLVENCLEXTAOral Daily DoseWeek 120 mgWeek 250 mgWeek 3100 mgWeek 4200 mgWeek 5 and beyond400 mgThe CLL/SLL Starting Pack provides the first 4 weeks of VENCLEXTA according to the ramp-up schedule.

10 The 400 mg dose is achieved using 100 mg tablets supplied in bottles [see How Supplied/Storage and Handling (16)]. In Combination with ObinutuzumabStart obinutuzumab administration at 100 mg on Cycle 1 Day 1, followed by 900 mg on Cycle 1 Day 2. Administer 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle for a total of 6 cycles. Refer to the obinutuzumab prescribing information for additional dosing Cycle 1 Day 22, start VENCLEXTA according to the 5-week ramp-up dosing schedule (see Table 1). after completing the ramp-up phaseon Cycle 2 Day 28, continue VENCLEXTA at a dose of 400 mg orally once daily from Cycle 3 Day 1 until the last day of Cycle 12.